TLDR:
- Enlaza Therapeutics raised $100M in Series A funding led by J.P. Morgan Asset Management’s Private Capital division.
- The company plans to use the funds to develop its covalent protein technologies and advance pipeline programs to the clinic.
Enlaza Therapeutics, a La Jolla, CA-based covalent biologic platform company, has raised $100M in Series A funding. The round was led by the Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from existing and new investors. The company intends to further develop its proprietary covalent protein technologies and advance pipeline programs to the clinic. Their proprietary covalent biologic platform, War-LockTM, creates therapeutic warheads that covalently bind to drug targets of interest. This technology enables specific covalent binding to target proteins, improving efficacy and reducing toxicities. Enlaza Therapeutics’ Board of Directors includes representatives from J.P. Morgan Private Capital, Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, Samsara BioCapital, and the CEO, Sergio Duron. This funding will support the expansion of their covalent protein drug platform and the advancement of lead assets towards clinical development.
